{"title":"How PD gave me more control over my life","authors":"Richard Blaine","doi":"10.1002/dat.20604","DOIUrl":"10.1002/dat.20604","url":null,"abstract":"<p>I have been a kidney patient all my life, but it was still a shock when, in 2003, my doctor told me that in a year I would be on dialysis or need a kidney transplant. During that year I discovered that not only were there several ways to undergo hemodialysis, there was another way to dialyze called peritoneal dialysis (PD). It didn't take long for me to realize that PD had advantages over hemodialysis that would make it more friendly to my lifestyle. I could do it almost anytime, anywhere, and fit it into my life rather than have it <i>control</i> my life. While on PD, I was able to travel with my wife on multi-day road trips, go on cruises, and fly out of state (including a 10-day trip to Hawaii). PD had fewer dietary restrictions, especially for fluid intake. It dialyzed 24/7, similar to my original kidneys. PD gave me more control over my life.</p><p>It was also very reassuring to know that help from my support staff was always only a phone call away. But, while nephrologists and clinic staff showed me how to undergo PD, and explained what medicines to take and when to take them, what I found I also needed was the advice and experiences of other patients who were living with PD every day. There were no support groups around at that time specific to PD, so my wife and I started one—Living Well with Kidney Disease—and it has been and continues to be very helpful for me and its members.</p><p>One lesson I learned early on was that, with this disease, time is not your friend. Regardless of the circumstances, if something doesn't feel right call your clinic or nephrologist as soon as possible. There can be serious consequences if you don't. I like to think of myself as captain of the good ship <i>Richard's Health</i>. I have a crew of doctors and nurses who will keep me on track for good health, but <i>only</i> if I tell them how I'm feeling in a timely manner.</p><p>I underwent PD for 22 months and was doing so well that for the first year I was very ambivalent about undergoing transplantation. I changed my mind after talking to a young woman at a transplant meeting who'd received a kidney four years prior, and I knew after talking with her that she was doing better health-wise than I was at the time.</p><p>When I received the call from my transplant coordinator she asked me a key question: “Richard, how are you?” I instantly knew that she had a kidney for me. Two hours later, at 9:15 pm, I was at the hospital, prepped and on the operating table. By 11:15 pm, I was off the table, and the kidney was working before they had me stapled up! The next morning, except for the tubes and wires, I would have been running up and down the hall. When my wife came in she exclaimed, “Boy, do you look good!”</p><p>On August 7 I will be 74, and two days later I will celebrate five years with my new kidney. I am so thankful that my donor, Trisha, was a caring person who listed herself as a donor in case the unthinkable happened. It did, and she donated both lung","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 8","pages":"376"},"PeriodicalIF":0.0,"publicationDate":"2011-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20604","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51500420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A how-to manual: The art of teaching buttonhole self-cannulation","authors":"Stuart Mott","doi":"10.1002/dat.20586","DOIUrl":"https://doi.org/10.1002/dat.20586","url":null,"abstract":"","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 7","pages":"315-322"},"PeriodicalIF":0.0,"publicationDate":"2011-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20586","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137524670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lilit A Sargsyan MD, Risheng Xu DO, Alicia Romero MD, Brett W. Stephens MD, Donald A Molony MD
{"title":"Recombinant tissue plasminogen activator reduces incidence of catheter malfunction and bacteremia","authors":"Lilit A Sargsyan MD, Risheng Xu DO, Alicia Romero MD, Brett W. Stephens MD, Donald A Molony MD","doi":"10.1002/dat.20573","DOIUrl":"10.1002/dat.20573","url":null,"abstract":"<p>Hemmelgarn B, Moist L, Lok C, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. <i>N Engl J Med.</i> 2011;364:303-312.</p><p>Malfunctioning and infected hemodialysis catheters increase morbidity, mortality, and the cost of care of hemodialysis patients. More than 50% to 70% of hemodialysis catheters will be expected to fail within the first year, with half to two-thirds of these failures attributable to catheter thrombosis.<span>1</span> Heparin has been shown to be superior to saline as a locking solution in preventing catheter malfunction. Only one study, however, has previously evaluated recombinant tissue plasminogen activator (rt-PA) as a locking solution for primary prevention of catheter failure rather than as a treatment of existing/suspected thrombosis. In addition, line-related sepsis constitutes up to 75% of deaths from infection among this population,<span>2</span> and infection risk increases in the presence of partial or complete thrombosis.<span>3</span></p><p>In this month's literature watch, we review a study by Hemmelgarn and colleagues designed to evaluate whether rt-PA administered once weekly as locking solution in substitution for the scheduled dose of heparin is superior to the current customary care of locking catheters with heparin only after each dialysis session, in preventing catheter malfunction (primary outcome) and infection (secondary outcome).</p><p>The ideal study design to investigate whether one intervention is superior to another is a randomized clinical trial (RCT) with masked allocation and determination of outcomes. The study by Hemmelgarn and colleagues represents a well-designed RCT with random allocation of the patients and full masking (blinding) of group assignment, in which the investigators evaluate whether a protocol including 1 mg of rt-PA as a locking solution used once a week in place of 5,000 U of heparin is superior to heparin alone in preventing catheter malfunction and bacteremia.</p><p>Participants were recruited from 11 Canadian hemodialysis centers within 2 weeks of a newly inserted hemodialysis catheter. Patients were excluded from the study if their catheters at baseline failed to function adequately, defined as a blood flow of at least 300 mL/min during the dialysis sessions immediately prior to randomization. Masked random treatment allocation in a 1:1 ratio was performed centrally with the use of a permuted-block design stratified according to center and catheter status (first ever catheter for patient or not). Catheter malfunction and catheter-related bacteremia episodes by pre-defined criteria were documented. Analysis of outcomes was conducted on an intention-to-treat basis. Additionally, a cost assessment of maintaining future catheter patency was conducted.</p><p>Although the study was originally designed for an enrollment of 340 patients to ensure 80% power to detect approximately a 34% reduction in the incidence of catheter mal","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 6","pages":"268-271"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20573","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51499603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anita Patel MD, John Robertson MD, Christine Darwin MD, Harold Locay MD, Ramon Añel MD, Sara Engstrand MS, John Hunter MS, Melissa Plone MA, Jose Cangiano MD
{"title":"Double-blind study comparing doxercalciferol and placebo in vitamin D-replete CKD patients","authors":"Anita Patel MD, John Robertson MD, Christine Darwin MD, Harold Locay MD, Ramon Añel MD, Sara Engstrand MS, John Hunter MS, Melissa Plone MA, Jose Cangiano MD","doi":"10.1002/dat.20583","DOIUrl":"10.1002/dat.20583","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> OBJECTIVE</h3>\u0000 \u0000 <p>No well-controlled studies of the safety and efficacy of active vitamin D analogues have been conducted in vitamin D-replete (25-hydroxyvitamin D ≥ 30 ng/mL) patients. This study assessed the safety and efficacy of doxercalciferol in vitamin D-replete patients with secondary hyperparathyroidism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> METHODS</h3>\u0000 \u0000 <p>This was a randomized, double-blind, placebo-controlled, parallel study. Twenty-four vitamin D-replete (exogenous ergocalciferol or intrinsically replete) patients with elevated intact parathyroid hormone (iPTH) were randomized to receive doxercalciferol or matching placebo capsules for 24 weeks. The dose was regularly titrated to achieve target iPTH levels (CKD Stage 3: ≤ 70 pg/mL; CKD Stage 4: ≤ 110 pg/mL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> RESULTS</h3>\u0000 \u0000 <p>Eleven (92%) doxercalciferol patients met the iPTH target range at least once post randomization compared with four (33%) placebo patients. All 12 (100%) doxercalciferol patients achieved a 30% reduction in iPTH at least once post randomization, and more doxercalciferol patients (83%) maintained iPTH within the target range for up to 6 weeks compared with the placebo patients (17%). Doxercalciferol and placebo were well tolerated during the study. No adverse events of hypercalcemia were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> CONCLUSIONS</h3>\u0000 \u0000 <p>Doxercalciferol was well tolerated and effective in reducing iPTH in vitamin D-replete CKD patients without accompanying hypercalcemia. Further studies in a larger population of vitamin D-replete patients are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51012,"journal":{"name":"Dialysis & Transplantation","volume":"40 6","pages":"252-257"},"PeriodicalIF":0.0,"publicationDate":"2011-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/dat.20583","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51500307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
